Overview

• Biotechnology firm's Q4 collaboration revenue more than doubled yr/yr, driven by GSK milestones

• Company reported Q4 net income, contrasting with a net loss last year

• AnaptysBio plans Q2 2026 spin-off of biopharma operations into public company to be called First Tracks Biotherapeutics

Outlook

• AnaptysBio plans to spin off biopharma operations in Q2 2026

• Company expects >$390 mln in annualized Jemperli royalties at peak sales, expected as early as 2029

• Top-line Phase 1b data for ANB033 expected in Q4 2026

Result Drivers

• JEMPERLI PERFORMANCE - GSK's Jemperli sales grew over 13% qtr/qtr, contributing to AnaptysBio's collaboration revenue increase

• ANB033 TRIALS - Phase 1b enrollment ongoing for ANB033 in celiac disease

• SPIN-OFF PREPARATION - AnaptysBio plans to spin off biopharma operations into First Tracks Biotherapeutics by Q2 2026

Company press release: ID:nGNX68cjcR

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for AnaptysBio Inc is $65.50, about 19.3% above its March 2 closing price of $54.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)